Patents Represented by Attorney, Agent or Law Firm Karen F. Clark
-
Patent number: 5637580Abstract: Compounds of structure: ##STR1## as well as their pharmaceutically-acceptable salts and biohydrolyzables esters, and hydrates thereof, are effective antiinfective agents, useful in treating and preventing infection.Type: GrantFiled: June 7, 1995Date of Patent: June 10, 1997Assignee: The Procter & Gamble CompanyInventors: Ronald E. White, Thomas P. Demuth, Jr.
-
Patent number: 5618835Abstract: A compound having the structure: ##STR1## pharmaceutical compositions comprising such compounds, and methods of treating inflammation or pain using such compounds.Type: GrantFiled: February 1, 1996Date of Patent: April 8, 1997Assignee: The Procter & Gamble CompanyInventors: Laurence I. Wu, John M. Janusz
-
Patent number: 5602227Abstract: The present invention relates to biodegradable PHA copolymers comprising at least two randomly repeating monomer units. The present invention further relates to a plastic article comprising a biodegradable copolymer, wherein the biodegradable copolymer comprises at least two randomly repeating monomer units (RRMU) wherein the first RRMU has the structure ##STR1## wherein R.sup.1 is H, or C.sub.1 or C.sub.2 alkyl, and n is 1 or 2; the second RRMU has the structure ##STR2## wherein R.sup.2 is a C.sub.4 -C.sub.19 alkyl or alkenyl; and wherein at least 50% of the RRMUs have the structure of the first RRMU. The present invention further relates to an absorbent article comprising a liquid pervious topsheet, a liquid impervious backsheet comprising a film comprising a PHA of the present invention and an absorbent core positioned between the topsheet and the backsheet.Type: GrantFiled: August 30, 1995Date of Patent: February 11, 1997Assignee: The Procter & Gamble CompanyInventor: Isao Noda
-
Patent number: 5578607Abstract: The subject invention relates to compounds having the structure: ##STR1## wherein: (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl;(b) R' is selected from unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy; thiol; and halo; and(c) R" is selected from hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; methyl monosubstituted with hydroxy, thiol or amino; unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; amino; unsubstituted amide; unsubstituted or C.sub.1 -C.sub.3 substituted amido; halo; unsubstituted sulfoxide; unsubstituted sulfonyl; and cyano;pharmaceutical compositions containing such compounds, and the use of such compounds for preventing or treating respiratory, ocular, and/or gastrointestinal disorders.Type: GrantFiled: October 20, 1994Date of Patent: November 26, 1996Assignee: The Procter & Gamble CompanyInventors: Thomas L. Cupps, Peter J. Maurer, Jeffrey J. Ares
-
Patent number: 5576437Abstract: The subject invention involves methods of treating nasal congestion comprising administration, to a human or lower animal in need of such treatment of a safe and effective amount of a compound having the following structure: ##STR1## wherein: (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; and(b) R' is selected from hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy; thiol; cyano; and halo.The subject invention also involves the use of such compounds for preventing or treating other respiratory, ocular and/or gastrointestinal disorders. The subject invention also involves novel compounds having the above structure wherein R' is hydrogen or fluoro or cyano.Type: GrantFiled: August 18, 1994Date of Patent: November 19, 1996Assignee: The Procter & Gamble CompanyInventors: Thomas L. Cupps, Sophie E. Bogdan
-
Patent number: 5541210Abstract: The subject invention involves compounds having the following structure: ##STR1## wherein: (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl;(b) R' is selected from hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy; thiol; cyano; and halo; and(c) R' is selected from hydrogen, methyl, ethyl and i-propyl.The subject invention also involves pharmaceutical compositions containing such novel compounds, compositions thereof and the use of such compounds for preventing or treating respiratory, ocular and/or gastrointestinal disorders.Type: GrantFiled: June 29, 1995Date of Patent: July 30, 1996Assignee: The Procter & Gamble CompanyInventors: Thomas L. Cupps, Sophie E. Bogdan
-
Patent number: 5519013Abstract: The present invention relates to novel heterocycle-substituted diphosphonic acids, and the pharmaceutically-acceptable salts and esters thereof, in which the diphosphonate-substituted carbon atom moiety is attached to a carbon atom in a nitrogen-containing six membered ring heterocycle, preferably a piperidine ring. The heterocycle-substituted diphosphonic acid compounds have the general structure: ##STR1## wherein Z is a nitrogen-containing six membered ring heterocycle moiety selected from piperidinyl, diazinyl and triazinyl; m, n and m+n are from 0 to 10; Q is a covalent bond or a moiety selected from oxygen, sulfur or nitrogen; and R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are substituent groups.The present invention further relates to pharmaceutical compositions containing these novel compounds. Finally this invention relates to methods for treating or preventing diseases characterized by abnormal calcium and phosphate metabolism by utilizing a compound or pharmaceutical composition of the present invention.Type: GrantFiled: April 7, 1994Date of Patent: May 21, 1996Assignee: The Procter & Gamble CompanyInventors: Frank H. Ebetino, James J. Benedict
-
Patent number: 5514663Abstract: This invention relates to a pharmaceutical laxative composition in unit dosage form, for peroral administration of sennosides to a human or other animal subject, comprising a safe and effective amount of sennosides in a rapidly dissolving matrix; and a proximal colonic delivery carrier which effects release of said sennosides substantially near the junction between the small intestine and the colon or within the colon of said subject. This invention also involves methods for providing laxation for humans and other animals in need thereof by peroral administration of such compositions.Type: GrantFiled: October 19, 1993Date of Patent: May 7, 1996Assignee: The Procter & Gamble CompanyInventor: Kenneth G. Mandel
-
Patent number: 5510361Abstract: The subject invention relates to compounds having the structure: ##STR1## wherein a) each R is independently alkyl having from 1 to about 7 carbon atoms;b) Z is O or N--X;c) X is selected from hydrogen, alkyl having from 1 to about 7 carbon atoms, C(O)Y, C(S)Y, and SO.sub.2 Y;d) Y is selected from R', OR' and NR'.sub.2 ; ande) R' is selected from hydrogen, alkyl having from 1 to about 7 carbon atoms, and phenyl.The subject invention also relates to pharmaceutical compositions comprising the above compounds, and methods of treating inflammation or pain using the compounds.Type: GrantFiled: October 20, 1994Date of Patent: April 23, 1996Assignee: The Procter & Gamble CompanyInventors: Michael W. Scherz, Stanislaw Pikul
-
Patent number: 5500208Abstract: The present invention relates to a tripepride having the amino acid sequence Alanine-lsoleucine-Phenylalanine. This invention also relates to methods and compositions for inhibiting growth of dental plaque on tissues within an oral cavity of a human or other animal comprising topical administration, to tissues of such oral cavity, of a composition comprising a safe and effective amount of the tripepride.Type: GrantFiled: June 7, 1994Date of Patent: March 19, 1996Assignee: The Procter & Gamble CompanyInventor: Duane L. Charbonneau
-
Patent number: 5500206Abstract: The present invention relates to compositions and methods for inhibiting or preventing growth of dental plaque on tissues within the human oral cavity comprising topical administration, to tissues of a human oral cavity, of a composition comprising a safe and effective amount of Actinomyces viscosus fimbriae.Type: GrantFiled: April 29, 1994Date of Patent: March 19, 1996Assignee: The Procter & Gamble CompanyInventor: Duane L. Charbonneau
-
Patent number: 5491139Abstract: Antimicrobial quinolonyl lactam compounds comprising a lactam-containing moiety linked, by a non-ester linking moiety, to the 3-carboxy group of a quinolone moiety. These compounds are of the formula: ##STR1## wherein (1) R.sup.3, R.sup.4, and R.sup.5, together with bonds "a" and "b", form any of a variety of lactam-containing moieties similar to those known in the art to have antimicrobial activity;(2) A, R.sup.6, R.sup.7, and R.sup.8 form any of a variety of quinolone or naphthyridine structures similar to those known in the art to have antimicrobial activity; and(3) Y, together with R.sup.5, form a variety of non-ester linking moieties between the lactam-containing moiety and the quinolone moiety.Type: GrantFiled: April 6, 1994Date of Patent: February 13, 1996Assignee: The Procter & Gamble CompanyInventors: Thomas P. Demuth, Jr., Ronald E. White
-
Patent number: 5462940Abstract: The 4-oxocyclic ureas and the pharmaceutically acceptable salts and esters thereof, of the present invention are useful as antiarrhythmic and antifibrillatory agents and have the following general structure: ##STR1## wherein X, Y, A, L, R, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are defined as in the specification.Type: GrantFiled: June 3, 1994Date of Patent: October 31, 1995Assignee: Norwich Eaton Pharmaceuticals, Inc.Inventors: Chia-Nien Yu, Stanford S. Pelosi, Jr., Mark A. Calcagno
-
Patent number: 5434147Abstract: Antimicrobial quinolonyl lactam esters comprising a lactam-containing moiety linked, by an ester group, to the 3-carboxy group of a quinolone moiety. These compounds are of the formula: ##STR1## wherein (1) R.sup.3, R.sup.4, and R.sup.5, together with bonds "a" and "b", form certain lactam-containing moieties similar to those known in the art to have antimicrobial activity; and(2) A, R.sup.6, R.sup.7, and R.sup.8 form any of a variety of quinolone or napthyridine structures similar to those known in the art to have antimicrobial activity.Type: GrantFiled: October 8, 1993Date of Patent: July 18, 1995Assignee: Proctor & Gamble Pharmaceuticals, Inc.Inventors: Ronald W. White, Thomas P. Demuth, Jr.
-
Patent number: 5393746Abstract: The present invention relates to novel compounds having nitrogen-containing, saturated bicyclic cylopentane-fused rings which are geminally disubstituted with phosphonate groups. Most preferred compounds of the present invention have the general structure: ##STR1## The present invention further relates to pharmaceutical compositions containing these novel compounds. Finally, this invention relates to methods for treating or preventing diseases characterized by abnormal calcium and phosphate metabolism by utilizing a compound or pharmaceutical composition of the present invention.Type: GrantFiled: June 17, 1992Date of Patent: February 28, 1995Assignee: P&G Pharmaceuticals, Inc.Inventors: Frank H. Ebetino, Kent W. Buckingham, Jocelyn E. McOsker
-
Patent number: 5391743Abstract: The present invention relates to quaternary nitrogen-containing phosphonate compounds, and the pharmaceutically-acceptable salts and esters thereof and having the general structure: ##STR1## wherein R.sup.1, R.sup.2, R.sup.5 and R.sup.8 are defined in claim 1, m and n are integers from 0 to 10; m+n is from 0 to 10;Z is a saturated, unsaturated, or aromatic, monocyclic or polycyclic carbocycle or monocyclic or polycyclic heterocycle containing one or more heteroatoms selected from O, S, or N, wherein at least one heteroatom is a quaternary nitrogen atom;R is COOH; PO.sub.3 H.sub.2 ; SO.sub.3 H; or P(O)(OH)R.sub.4, wherein R.sub.4 is substituted or unsubstituted alkyl of 1-8 carbon atoms;The present invention further relates to pharmaceutical compositions containing a safe and effective amount of a compound of the present invention, and pharmaceutically-acceptable excipients.Type: GrantFiled: April 30, 1993Date of Patent: February 21, 1995Assignee: Procter & Gamble Pharmaceuticals, Inc.Inventors: Frank H. Ebetino, Susan M. Kaas, Marion D. Francis, Dennis G. A. Nelson, John M. Janusz
-
Patent number: 5387748Abstract: Antimicrobial dithiocarbamoyl quinolone compounds of the general formula: ##STR1## wherein (1) A.sup.1, A.sup.2, A.sup.3, R.sup.1, R.sup.3, R.sup.4, and R.sup.6 form any of a variety of quinolone and related heterocyclic structures similar to those known in the art to have antimicrobial activity; and(2)(1) R.sup.1 is X, R.sup.3 is X, or both R.sup.1 and R.sup.3 are X; and(2) X is --R.sup.15 --N(R.sup.16)(R.sup.17) or --R.sup.15 --R.sup.18 --N(R.sup.19)(R.sup.17), where(a)(1) R.sup.15 is nil, alkyl, a carbocyclic ring, or a heterocyclic ring; and(2) R.sup.16 is hydrogen; alkyl; alkenyl; a carbocyclic ring; a heterocyclic ring; or(3) when X is R.sup.15 --N(R.sup.16)(R.sup.17), R.sup.16 and R.sup.15 may together comprise a heterocyclic ring including the nitrogen atom to which R.sup.15 and R.sup.16 are bonded;(b) R.sup.17 is C(.dbd.S)--S--M, where M is a pharmaceutically-acceptable salt or biohydrolyzable ester; and(c)(1) R.sup.18 is alkyl, a carbocyclic ring, or a heterocyclic ring; and(2) R.sup.Type: GrantFiled: May 2, 1991Date of Patent: February 7, 1995Assignee: Procter & Gamble Pharmaceuticals, Inc.Inventors: Thomas P. Demuth, Jr., Ronald E. White
-
Patent number: 5334586Abstract: The present invention relates to novel heterocycle-substituted diphosphonic acids, and the pharmaceutically-acceptable salts and esters thereof, in which the diphosphonate-substituted carbon atom moiety is attached to a carbon atom in a nitrogen-containing six membered ring heterocycle, preferably a piperidine ring. The heterocycle-substituted diphosphonic acid compounds have the general structure: ##STR1## wherein Z is a nitrogen-containing six membered ring heterocycle moiety selected from piperidinyl, diazinyl and triazinyl; m, n and m+n are from 0 to 10; Q is a covalent bond or a moiety selected from oxygen, sulfur or nitrogen; and R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are substituent groups.The present invention further relates to pharmaceutical compositions containing these novel compounds. Finally this invention relates to methods for treating or preventing diseases characterized by abnormal calcium and phosphate metabolism by utilizing a compound or pharmaceutical composition of the present invention.Type: GrantFiled: October 21, 1991Date of Patent: August 2, 1994Assignee: Procter & Gample Pharmaceuticals, Inc.Inventors: Frank H. Ebetino, James J. Benedict
-
Patent number: 5328908Abstract: Antimicrobial quinolone thiourea compounds of the general formula: ##STR1## wherein (1) A.sup.1, A.sup.2, A.sup.3, R.sup.1, R.sup.3, R.sup.4, and R.sup.6 form any of a variety of quinolone and related heterocyclic structures similar to those known in the art to have antimicrobial activity; and(2)(1) R.sup.1 is X, R.sup.3 is X, or both R.sup.1 and R.sup.3 are X; and(2) X is --R.sup.15 --N(R.sup.16)(R.sup.17) or --R.sup.15 --R.sup.18 --N(R.sup.19)(R.sup.17), where(a)(1) R.sup.15 is nil, alkyl, a carbocyclic ring, or a heterocyclic ring; and(2) R.sup.16 is hydrogen; alkyl; alkenyl; a carbocyclic ring; a heterocyclic ring; or(3) when X is R.sup.15 --N(R.sup.16)(R.sup.17), R.sup.16 and R.sup.15 may together comprise a heterocyclic ring including the nitrogen atom to which R.sup.15 and R.sup.16 are bonded;(b) R.sup.17 is C(.dbd.S)--NR.sup.20 R.sup.21 ; where R.sup.20 is, hydrogen, alkyl, alkenyl, a carbocyclic ring or a heterocyclic ring; and R.sup.21 is R.sup.20 or N(R.sup.20)(R.sup.20); or R.sup.20 and R.sup.Type: GrantFiled: April 20, 1990Date of Patent: July 12, 1994Assignee: Procter & Gamble Pharmaceuticals, Inc.Inventors: Thomas P. Demuth, Jr., Ronald E. White
-
Patent number: 5273973Abstract: Antimicrobial quinolnyl lactam esters comprising a lactam-containing moiety linked, by an ester group, to the 3-carboxy group of a quinolone moiety. These compounds are of the formula: ##STR1## wherein (1) R.sup.3, R.sup.4, and R.sup.5, together with bonds "a" and "b", form certain lactam-containing moieties similar to those known in the art to have antimicrobial activity; and(2) A, R.sup.6, R.sup.7, and R.sup.8 form any of a variety of quinolone or napthyridine structures similar to those known in the art to have antimicrobial activity.Type: GrantFiled: August 21, 1992Date of Patent: December 28, 1993Assignee: Norwich Eaton Pharmaceuticals, Inc.Inventors: Ronald E. White, Thomas P. Demuth, Jr.